Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
09 October 2020 Photo Supplied
Kgalalelo Motlhabane
A Master of Commerce degree with specialisation in Industrial Psychology will be conferred on Kgalalelo Motlhabane, a graduate and funding officer at the Postgraduate School at UFS on Friday 9 October 2020 in a virtual graduation.

One of the success stories of this year’s virtual graduation is Kgalalelo Motlhabane, a graduate and funding officer at the Postgraduate School, University of the Free State (UFS), who was presented with an award from the National Research Foundation as the best designated authority for 2019.

Motlhabane, who lost her mother when she was in high school, didn’t just have to overcome poverty on her way to her first qualification, but also the fear of ending up on the street. On Friday 9 October she received a Master of Commerce degree with specialisation in Industrial Psychology.

A lot of challenges

“I had a lot of challenges during my first-year undergraduate studies. I could not afford textbooks and stationery. I spent most of my time in the library studying. More often I would be without food and proper clothes to wear.

“I would get warnings from my landlord when the rent was late. Sometimes I would find my room locked and my personal stuff removed. Not being able to pay outstanding fees restricted me from receiving my final results at the end of semesters and exacerbated the situation,” says Motlhabane.

Regardless of all these challenges, she was determined to not give up and return home to the impoverished community of Itireleng village near Pampierstad in the Northern Cape.

Overcoming the challenges

It was actually the distress, poverty and the difficult situation at home, together with her daily struggles that kept her focused. Through hard work, she managed to receive funding from NSFAS for her second and third years and despite the hardships, she obtained her BSocSci degree with distinction at the end of 2012.

“I was then selected to enroll for an Honours degree in Industrial Psychology in 2013. Without any funding prospects for my studies, I wrote to the former university rector Prof Jonathan Jansen, seeking financial assistance.

“Prof Jansen was very impressed with my exceptional academic performance and offered to pay my fees. He also offered me a position to work as a student assistant. I worked for three hours every day before going to the library to do my assignments and prepare for classes, presentations, tests and exams. I completed my Honours degree in 2013.”

In 2014, Motlhabane was employed as an intern at the UFS Human Resources Department and also enrolled for a postgraduate diploma in gender studies, which she obtained at the end of that year. The following year she joined the postgraduate school and started with her Master’s degree in late 2016.

Obtaining a Master’s degree

This was no easy task as she was employed full time which left her with little time to work thoroughly on her thesis, her limited knowledge about research, work pressures and demands, rejections, lack of support, discouragements, accidents and the inability to cope also played a role.  

“I would like to thank God for the strength he gave me to cope throughout my journey, my family for their prayers and continued support, as well as Prof Jonathan Jansen, Prof Petrus Nel and Prof Ebben van Zyl for their kind support and contribution towards my studies. Indeed, the future belongs to those who believe in the beauty of their dreams,” says Motlhabane.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept